Twist Bioscience(TWST) - 2025 Q2 - Earnings Call Presentation

Financial Performance - Second quarter fiscal year 2025 revenue reached $92.8 million[18,42] - The company's gross margin was 49.6%[18,42], progressing towards exceeding 50% by the fourth quarter of fiscal year 2025[18] - Adjusted EBITDA loss was $(14.8) million[18,42], beating guidance[18] Business Segment Highlights - SynBio revenue was $36.0 million, a 21% year-over-year growth, with approximately 227,000 genes shipped[22] - NGS revenue was $51.1 million, a 25% year-over-year growth[25] - Biopharma Solutions revenue was $5.7 million, a 21% year-over-year growth, with $6.4 million in orders[28] Atlas Data Storage - Atlas Data Storage launched with $155 million in funding from leading investors[11,13] Fiscal Year 2025 Guidance - The company anticipates full fiscal year 2025 revenue to be between $372 million and $379 million[45] - The company anticipates full fiscal year 2025 adjusted EBITDA to be between $(48) million and $(53) million[45]